Study #2023-0517
A phase 1 first-in-human study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
CLN-617, Pembrolizumab
Description
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Adi Diab
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.